(Q37990977)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22394203%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

title

Sorafenib in melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22394203%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Joanna Mangana

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22394203%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Maria B Karpova

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22394203%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

language of work or name

English

0 references

publication date

7 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22394203%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

25 January 2020

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22394203%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22394203%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22394203%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

557-568

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22394203%20AND%20SRC:MED&resulttype=core&format=json

Improving outcomes in advanced malignant melanoma: update on systemic therapy

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Epidemiology of invasive cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Systematic review of medical treatment in melanoma: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Sorafenib-induced premalignant and malignant skin lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

BAY 43-9006 inhibition of oncogenic RET mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Angiogenesis, lymphangiogenesis, and melanoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Design and discovery of small molecules targeting raf-1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

A phase II trial of sorafenib in metastatic melanoma with tissue correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Phase II study of paclitaxel and carboplatin for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Sorafenib for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Eruptive nevi associated with sorafenib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Toxicity of sorafenib: clinical and molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Modeling genomic diversity and tumor dependency in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Sorafenib: a review of its use in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Updated Swiss Guidelines for the Treatment and Follow-Up of Cutaneous Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.665872

10.1517/13543784.2012.665872

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22394203%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference